Argenx Hosts R&D Webinar on Autoimmune Myositis Treatments
Argenx, an immunology specialist, is hosting a webinar today dedicated to its research and development in autoimmune myositis. The event brings together the company's scientific leadership and external experts, highlighting its commitment to this therapeutic field.
A Presentation Focused on FcRn Technology
The webinar, titled 'R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis', is scheduled for Tuesday, June 23 at 2:00 PM (New York time). Argenx will present its work on neonatal Fc receptor (FcRn) blockers, its flagship technology developed to treat severe autoimmune diseases. The presentation explores the potential of this approach applied to myositis, a group of inflammatory diseases affecting the muscles.
Expertise Gathered in Rheumatology and Neurology
Argenx's scientific leadership is joined by three recognized experts: Avery LaChance (Associate Professor of Dermatology at Harvard Medical School, Director of the Connective Tissue Disease Clinic), Arjun Seth (Assistant Professor in Neurology (Neuromuscular Diseases) at Northwestern University Feinberg School of Medicine), and Rohit Aggarwal (Professor at the University of Pittsburgh, Co-Director of the Myositis Center at UPMC). This lineup underscores the involvement of multiple medical specialties in exploring this therapeutic indication. The event is part of a series of communications highlighting the group's R&D portfolio in immunology and the clinical data of its candidates. A live broadcast will be available on Argenx's Investors site, along with a recording preserved for one year.
